These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 32967632)

  • 1. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
    Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
    BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
    Chae H; Cho H; Yoo C; Kim KP; Jeong JH; Chang HM; Kang J; Lee HC; Lim YS; Kim KM; Shim JH; Lee SS; Park DH; Song TJ; Hwang S; Song GW; Moon DB; Lee YJ; Lee JH; Ryoo BY
    Int J Biol Markers; 2018 Nov; 33(4):432-438. PubMed ID: 29874985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Ogata Y
    Oncology; 2019; 96(6):290-298. PubMed ID: 30909286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma.
    Kitano Y; Yamashita YI; Yamamura K; Arima K; Kaida T; Miyata T; Nakagawa S; Mima K; Imai K; Hashimoto D; Chikamoto A; Baba H
    Anticancer Res; 2017 Jun; 37(6):3229-3237. PubMed ID: 28551669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
    Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
    Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
    Cho H; Yoo C; Kim KP; Jeong JH; Kang J; Chang HM; Lee SS; Park DH; Song TJ; Lee SK; Kim MH; Lee HC; Lim YS; Kim KM; Shim JH; Hwang S; Song GW; Moon DB; Lee JH; Lee YJ; Ryoo BY
    Invest New Drugs; 2018 Jun; 36(3):496-502. PubMed ID: 29192354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.
    Lee SY; Kim HS; Choi YJ; Park KH; Shin SW; Kim YH; Tae Kim S
    Am J Ther; 2016; 23(6):e1449-e1455. PubMed ID: 25285672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
    Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
    Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
    JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy.
    Choi YH; Lee JW; Lee SH; Choi JH; Kang J; Lee BS; Paik WH; Ryu JK; Kim YT
    Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1045-1051. PubMed ID: 30842131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
    Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
    World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
    Maßmann M; Treckmann J; Markus P; Schumacher B; Albers D; Ting S; Mende B; Roehrle J; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Schmid KW; Baba H; Siveke JT; Paul A; Schildhaus HU; Schuler M; Wiesweg M; Kasper S
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5085-5094. PubMed ID: 36334155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease.
    Sellers CM; Uhlig J; Ludwig JM; Stein SM; Kim HS
    Cancer Med; 2019 Oct; 8(13):5916-5929. PubMed ID: 31429524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
    Lee BM; Chung SY; Chang JS; Lee KJ; Seong J
    Gut Liver; 2018 May; 12(3):342-352. PubMed ID: 29409306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
    Ogul A; Kidi MM; Buyuksimsek M
    J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.